Cell Therapy Associated With Endobronchial Valve

Inclusion Criteria

• •Diagnosis of severe heterogeneous pulmonary emphysema (at least 10% of total lung parenchyma or 25% of target lobe with density \< -950HU);
• •Heterogeneity\> 15pp (difference of at least 15 percentage points of lung parenchyma with density greater than -950HU between the treated lobe(s) and the remaining lung on the same side)
• •Estimates of low or non-existent collateral ventilation (fissure integrity\> 95% measured by VIDA Diagnostics or collateral ventilation measured by negative Chartis® System)
• •Total lung capacity\> 100% of predicted
• •Residual volume\> 175% of predicted
• •FEV1 \<50% of predicted post-bronchodilator
• •DLCO (diffusing capacity of the lungs for carbon monoxide) \<45% of predicted post-bronchodilator
• •Body Mass Index (BMI) Greater than 18Kg/m2 and less than 35Kg/m2.
• •Optimized clinical treatment
• •Daily physical activities limitation
• •Possibility of pulmonary rehabilitation
• •Preserved ventricular function (LVEF\> 40%)
• •Cessation of smoking ≥ 4 months
• •Dyspnea MMRC ≥ 2